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Chapter I 
 
 
 
BACKGROUND AND INTRODUCTION 
 
 
 
Muscarinic acetylcholine receptors (mAChRs) are cell surface receptors 
which mediate responses to the endogenous neurotransmitter acetylcholine at 
parasympathetically innervated effector tissues (Wess et al., 1996).  The 
mAChRs are expressed in nearly all parts of the central nervous system.  In the 
central nervous system the mAChR subtype 1 (M1) has been discovered to play 
a role in processes of cognition (Messer et al., 1990), learning, control of 
movement, and the initiation of seizures (Hamilton et al., 2001).  Complete 
understanding of the multiple mechanisms of M1 receptor function and regulation 
would allow progression in drug design and development for clinical treatment.  
The goal of this research is to understand more thoroughly the role of individual 
amino acid residues in a small domain in the human mAChR subtype 1 (hM1) 
intracellular loop 3 (i3) on receptor internalization. 
 
 
1.1  History of Muscarinic Receptors 
Preliminary studies as early as 1869 identified a substance, which was 
called muscarine, from the poisonous mushroom (Amanita muscaria) that would 
slow, and at high concentrations arrest, the beat of a frog heart (Brown, 1989).
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In 1877, Schmiedeberg and Harnack found that when choline was treated with 
fuming nitric acid, a substance was formed that appeared to have the same 
pharmacological actions as muscarine (see review, Brown, 1989).  Further 
investigation by Henry Hallet Dale in 1914 found that the pharmacology of the 
two substances, muscarine and the Schmiedeberg substance, were different and 
that the choline derived substance, later identified as acetylcholine, also had 
considerable nicotinic activity (see review, Brown, 1989).  This discovery allowed 
for the classification of the actions of acetylcholine to be divided into nicotinic and 
muscarinic actions.  Muscarinic (mAChR) and nicotinic (nAChR) cell surface 
receptors are both activated by the same neurotransmitter acetylcholine but are 
members of two quite different receptor gene superfamilies.  Muscarinic 
receptors are selectively activated by muscarine and blocked by atropine, an 
alkaloid derived from the deadly nightshade (Atropa belladonna); nicotinic 
receptors are activated by nicotine and blocked by d-tubocurarine (Hulme et al., 
1990).   
 
1.2  Classification of Muscarinic Receptors 
As shown in Figure 1, muscarinic receptors are class 1 rhodopsin-like G-
coupled receptors (GPCR) with an extracellular N-terminus, seven 
transmembrane (TM) domains, three extracellular loops, three intracellular loops 
and an intracellular C-terminus tail (Hulme et al., 1990).  The transmembrane 
regions have the highest homology between the different subtypes of muscarinic 
 Figure 1.  Diagram of the protein sequence of human mAChR 1 (Shockley, 1991) 
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receptors and other members of the G-protein family (Hulme et al., 1990).  
Ligand binding to the TM core of the receptor changes the conformation of the 
receptor activating G-proteins, setting off a course of actions attributed to all 
GPCRs (Dohlman et al., 1991; Savarese and Fraser, 1992; Strader et al., 1994).  
Binding of the ligand is predicted to occur specifically in a pocket formed by the 
transmembrane domains and involves several conserved amino acid residues 
(Wess, 1993). 
 
1.2.1  Subtypes of Muscarinic Receptors 
Historically, receptor classification has been approached by the discovery 
of receptor selective antagonists and agonists.  Receptors are defined by the 
agonist(s) and antagonist(s) that bind but in the case of muscarinic receptors this 
approach suggested the existence of subtypes.  For example, the antagonist 
pirenzepine, which has a higher affinity for muscarinic receptors found in 
neuronal tissue over receptors found in cardiac and smooth muscle, gave the 
first indication of muscarinic receptor subtypes (Hammer et al., 1980).  All 
subtypes of muscarinic receptors bind the agonist acetylcholine and the 
antagonist atropine.  Unfortunately, no exclusively selective agonist has been 
described for muscarinic receptors.  Complicating further classification, selective 
antagonists show relatively low selectivity (i.e., 10 to 20 fold lower affinity) 
between the subtypes (Brown, 1989).      
Utilizing pharmalogical binding studies, and advancements in molecular 
biology, five subtypes of muscarinic receptors have been identified.  These five 
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subtypes of human mAChRs (hM1 – hM5), encoded by separate genes, have 
been cloned (Bonner et al., 1987; Caulfield and Birdsall, 1998; Kubo et al., 1986; 
Peralta et al., 1987).  Each mAChR subtype is encoded by a single exon and 
expressed as a single polypeptide in vivo (Matsui et al., 1999).  
Comparing the sequences of the M1 – M5 receptors, the major amino acid 
differences are located in the extracellular amino terminus, the cytoplasmic 
carboxy terminus, and the third intracellular loop (i3).  The greatest difference in 
sequences between the subtypes are in the i3 loop but there is more homology 
between M1, M3, and M5 receptors, than M2 and M4 receptors which are more 
homologous to each other.   The homology of the i3 loop between M1, M3, and M5 
receptors, and M2 and M4 receptors is mainly in the amino- and carboxy-terminal 
portions, and has been postulated to be involved in the coupling of G-proteins 
(Wess, 1996).    
Muscarinic receptors are expressed in specific cells but tissues can have 
a mixture of different muscarinic subtypes expressed adding an additional 
complication in defining subtypes.  In general, M1 is mainly found in the forebrain, 
especially in the hippocampus and cerebral cortex and ganglia (Caulfield and 
Birdsall, 1998; Dorje et al., 1991; Felder et al., 2001; Levey et al., 1991).  M2 is 
expressed in mammalian myocardium and brainstem (Caulfield and Birdsall, 
1998; Ehlert and Tran, 1990).  M2 is also the major muscarinic receptor 
expressed in smooth muscle (Candell et al., 1990).  M3 is a minor fraction of total 
receptor population and can be found in smooth muscle, exocrine glands, 
endocrine glands, and cerebral cortex (Caulfield and Birdsall, 1998).  M4 can be 
5 
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found in the neostriatum and the forebrain (Caulfield and Birdsall, 1998; Yasuda 
et al., 1992).  M5 is found at very low levels in the hippocampus, striatum, and 
brainstem (Eglen and Nahorski, 2000).  
 
1.2.2  M1 Muscarinic Receptor Subtype 
The hM1 gene resides on chromosome 11 and consists of one large exon 
containing the entire coding region of the hM1 receptor (Lucas et al., 2001; 
Matsui et al., 1999).  The hM1 AChR is also called the neuronal muscarinic 
receptor because it is found predominantly in the cortex and hippocampus 
(Levey, 1993).  The M1 receptor is involved in many processes such as the 
initiation of seizures, learning and memory (Hamilton et al., 1998).  In the 
cerebral cortex, gene knockout studies have suggested that the M1 receptor is 
responsible for the entire cholinergic component of mitogen-activated protein 
(MAP) kinase stimulation (Hamilton and Nathanson, 2001), mediating effects on 
synaptic plasticity and cognition (Rosenblum et al., 2000). 
M1, M3, and M5 mAChRs couple preferentially to G proteins of Gq/G11 
class leading to the breakdown of phosophoinositides and do not inhibit adenylyl 
cyclase (Offermanns et al., 1994).  M2 and M4 preferentially couple to Gi and 
inhibit adenylyl cyclase (Offermanns et al., 1994).  As shown in Figure 2, the 
coupling of M1 to the Gq/G11 G protein leads to the activation of phospholipase C 
(PLC) which hydrolyzes phosphoinositol-4,5-bisphosphate (PIP2) to generate the 
second messengers inositol-1,4,5-triphoshate (IP3), and diacylglygerol (DAG).  
IP3 can be recycled back into PIP2 or binds to receptors on the endoplasmic 
Figure 2.  M1 receptor signaling.  A) M1 receptor.  B) Binding of agonist to the M1 receptor activates the G-protein by 
initiating the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the α subunit.  The Gq/11 α-
subunit dissociates from the βγ complex.  C) The α subunit binds and activates the PLC.  D)  PLC hydrolyzes PIP2, which 
generates IP3 and DAG.  IP3 binds to receptors on the endoplasmic reticulum to release intracellular Ca2+.  E)  DAG 
activates PKC which can phosphorylate proteins.
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reticulum to release calcium from intracellular stores (Jones et al., 1990).  DAG 
can be recycled back into PIP2 through a series of reactions or can activate 
protein kinase C (PKC).  The activated form of PKC can then phosphorylate 
proteins such as the M1 receptor.     
 
1.3.  Regulation of Expression and Function of AChR 
 Distribution of G protein coupled receptors on the cell surface is 
maintained by two processes that transport the receptors throughout the cell.  
The first process involves newly synthesized receptors from the rough 
endoplasmic reticulum transported to the Golgi complex, processed and 
transported to the cell surface by transport vesicles.  Endocytosis is the second 
process and describes receptors moving from the cell surface into internal 
endosome compartments because of basal rate (slow) endocytosis or agonist-
stimulated (fast) endocytosis (Koenig and Edwardson, 1997).  The path taken by 
the majority of receptors after reaching the endosome is to be recycled back to 
the cell surface, but the receptors can also be directed to lysosomes for 
degradation (Koenig and Edwardson, 1997).   
Prolonged agonist exposure activates a regulatory mechanism that 
causes desensitization (loss of functional response), quickly ending agonist-
induced stimulation.  Desensitization can be homologous, whereby only the 
activated receptors are desensitized, or heterologous, whereby activation of one 
receptor system may produce signals that feedback on another receptor.  
Typically desensitization is recognized by the muscarinic receptors losing high 
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affinity binding, uncoupling from G proteins and internalizing to a ligand 
inaccessible compartment.  Extended (hours) agonist exposure can cause down-
regulation of the receptor by either increasing the degradation of existing proteins 
or by a decrease in the synthesis of new receptors (Wang et al., 1990). 
 
1.3.1  Phosphorylation and Uncoupling from G Proteins 
Agonist bound G protein-coupled receptors are phosphorylated by G 
protein-coupled receptor kinases and cytosolic β-arrestins bind with increased 
affinity to the receptors and sterically inhibit further coupling of the receptors with 
G proteins (Krupnick and Benovic, 1998).  Phosphorylation of hM1 receptors 
normally occurs at serine/threonine residues in the C-terminus tail and/or the i3 
loop (Haga et al., 1996).   
There are two types of serine/threonine kinases that phosphorylate 
muscarinic receptors.  The first are second messenger kinases that include 
protein kinase A (PKA) and protein kinase C (PKC).  Heterologous 
desensitization on M1 receptors can be mediated by PKC and phosphorylation 
occurs at two to three sites punitively located in the carboxy-terminal part of the 
i3 loop and the carboxy-terminal tail (Haga et al., 1996).  The second type of 
kinases are the G protein-coupled receptor kinases (GRKs) which phosphorylate 
receptors that are in an active state (Palczewski and Benovic, 1991).  GRKs are 
a family of seven kinases (GRK 1-7) where GRKs 2,3,4,5, and 6 regulate most 
GPCRs (Lefkowitz and Shenoy, 2005).  Agonist-dependent phosphorylation of 
hM1 receptors is thought to occur by GRK2 on four to five sites in a 
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serine/threonine rich domain located in the central portion of the i3 loop (Haga et 
al., 1996). 
 
1.3.2  Internalization 
Internalization is the loss of receptors on the cell surface without loss of 
total cellular receptor binding sites.  Overall, the mechanism by which agonist 
stimulation of muscarinic receptors causes internalization is not completely 
understood, and understanding is complicated by mechanisms differing 
depending on cell type and subtype. 
Internalized M1 receptor can be recycled to the cell surface or 
compartmentalized into a lysosome for down-regulation.  hM1 receptors have 
been shown to internalize into non-coated vesicles in CC137 cells (Raposo et al., 
1987), in an arrestin (cytosolic protein) independent but dynamin-dependent 
pathway in HEK-tsA201 cells (Lee et al., 1998), and in intracellular clathrin-
coated vesicles following agonist stimulation in HEK293 cells (Tolbert and 
Lameh, 1996) and CHO-K1 cells (Shockley et al., 1997).  The loss of receptors 
from the cell surface in response to agonist stimulation differs by cell type in 
which the receptor is expressed (Koenig and Edwardson, 1997 )  
The domains correlated with internalization of the M1 receptor have been 
shown to be located in the i3 loop.  Large deletions of the i3 loop have impaired 
internalization (Maeda et al., 1990), and various smaller deletions in the i3 loop 
have been identified to impair or to partially impair internalization (Lameh et al., 
1992).  The smaller deletion mainly focused on by investigators is a 
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serine/threonine (286-ESLTSSE-292) rich domain (Moro et al., 1993), which later 
has been shown to be involved in down-regulation rather that internalization 
(Shockley et al., 1999). 
 
1.3.3  Down-Regulation 
Down-regulation is defined by the loss of total receptor numbers as a 
consequence of receptor degradation.  In contrast to short-term desensitization, 
which occurs on a time scale of minutes without a decrease in total cellular 
receptor number, down-regulation occurs over several hours (Taylor et al., 1979).  
The decreased concentration of receptors after translocation to lysosomes are 
mechanisms involved in receptor down-regulation (Habecker and Nathanson, 
1992; Klein et al., 1979).  Since receptor endocytosis precedes receptor down-
regulation, specific investigations into down-regulation distinguished from 
internalization are problematic.  hM1 receptor down-regulation in CHO-K1 cells 
has been found to be differentially regulated from receptor internalization and 
mutations that impair down-regulation also affect G-protein coupling (Shockley et 
al., 1997).  In contrast to CHO-K1 cells, HEK293 cells have not shown any ability 
to down-regulate the M1 receptor (Moro et al., 1994).   
 
1.4  Significance of Study 
The emphasis of this research is to characterize a small domain located in 
the i3 loop of the hM1 receptor that has been previously shown to affect agonist-
dependent internalization.  The mechanism for muscarinic receptor 
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internalization is not completely understood, and previous research has been 
based on a larger portion of the i3 loop of the hM1 receptor.  Narrowing down the 
specific amino acids involved in hM1 receptor internalization will aide in the future 
identification of the specific mechanism involved. 
 
1.4.1  Discovery of 8 Amino Acid Domain 
 Dimerization is a familiar theme in the regulation of signal transduction. 
Several members of the GPCR category of cell surface receptors, even though 
generally believed to function as monomers, have been found to function as 
multimers (Terrillon and Bouvier, 2004).  Studies have concluded that 
dimerization under at least some conditions are common events in muscarinic 
receptors (Maggio et al., 1993; Park et al., 2001; Wreggett and Wells, 1995; 
Zeng and Wess, 1999).  Human M2 receptors have been determined to be 
capable of forming dimmers in Sf9 cells and retain their dimerization status 
under a variety of conditions (Park et al., 2001). Deletion analysis of chimeric 
α2Adrenergic/M3 muscarinic receptor chimeras have shown that dimerization can 
occur in the M3 receptor (Maggio et al., 1993).  Further investigation of 
dimerization of M3 receptors implicated that the size of the i3 loop of muscarinic 
receptor was important in the regulation of receptor dimerization (Maggio et al., 
1996).     
The implication that the size of the i3 loop in M3 was important in 
dimerization led to the investigation of the i3 loop in hM1 and its capability of 
interacting (forming dimers) with itself.  Previously, our laboratory used the yeast 
12 
13 
two-hybrid system to identify an 8 amino acid (aa) domain in the i3 loop of hM1.  
Briefly, the yeast two-hybrid system is a molecular genetic tool which utilizes a 
bait and prey technique which facilitates the study of protein-protein interactions.  
The bait protein is expressed as a fusion with the GAL 4 DNA binding domain 
while another protein, prey, is expressed as a fusion to the GAL 4 activation 
domain.  When “bait” and “prey” interact with each other in a yeast reporter 
strain, the DNA binding domain and activation domain are brought into proximity 
and activate the transcription of reporter genes.  Neither the DNA binding domain 
nor activation domain can activate a reporter gene alone.  In our laboratory, 
multiple deletions in the hM1 i3 loop were made as “prey” and expressed with full 
length i3 loop “bait”.  The “prey” deletion constructs activated the reporter genes 
when expressed with the “bait”, with the exception of one that had a deletion of 8 
amino acids (Figure 3). 
  
Figure 3.  hM1 i3 loop constructs used in yeast two-hybrid experiments.  Multiple deletions of the “prey” i3 loop 
fusion protein were made (B-I) and expressed with full-length (aa 211-362) “bait” i3 loop fusion proteins (A) in 
AH109 to identify the domain mediating an interaction between full-length i3 loop fusion proteins.  All “prey” i3 loop 
fusion proteins (B-I) interacted with moderate affinity with the “bait” i3 loop construct except for F, which deleted the 
8 amino acids 254-TPPGRCCR-262 (unpublished observations by Ricks, T.K. and Sawyer, G.W.) 
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 A mutant hM1 receptor was made by mutagenesis, deleting only the 8 
amino acids (254-TPPGRCCR-261) from the i3 loop.  Pharmacological assays 
were performed to determine the functional role of this 8 amino acid domain.  
This mutant hM1 (hM1/8 aa del) receptor was compared to wild-type hM1 
(hM1/WT) receptor, in assays that measure agonist-induced internalization, 
saturation radioligand binding, phosphoinositide hydrolysis and down-regulation. 
 It was concluded that the hM1/8 aa del internalized less extensively than 
the hM1-WT receptor when incubated with the agonist carbachol (Figure 4).  
Although there was a significant difference in internalization of the receptors, the 
affinity of [3H]NMS binding and the potency of phosphoinositide hydrolysis when 
elicited to the agonist carbachol, was similar for hM1/8 aa del mutant and hM1/WT 
(unpublished observations).  Down-regulation after 24 hr exposure to the agonist 
carbachol was similar for both the hM1/8 aa del and hM1/WT receptor 
(unpublished observations).  Collectively, the data suggests that the 8 amino acid 
domain in the hM1 i3 loop plays an important role in agonist-dependent 
internalization.  
15 
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Figure 4.  Agonist-dependent internalization of hM1/WT and hM1/8 aa del 
receptors.  Mutant hM1 receptors lacking the 8 amino acid domain 254-
TPPGRCCR-261 in the i3 loop, internalized less extensively than the hM1/WT 
receptors when incubated with the agonist carbachol.  CHO-K1 cells expressing 
either hM1/WT () or hM1/8 aa del mutant (T) were incubated with carbachol (1 
mM) for up to 4 hour before conducting binding assays with [3H]NMS.  Each data 
point represents the mean ± S.E.M. of four experiments conducted in triplicate.  
¹ Denotes statistically significant differences (p < 0.05) between data points 
determined by student’s t-test (unpublished observations by Ricks, T.K. and 
Sawyer, G.W.) 
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1.4.2  Experimental Approach to Characterize a Small Domain in the I3 
Loop of the hM1 Receptor 
 
My experimental approach includes three components (Figure 5).  The 
first component of the study includes utilizing a protein motif scan to identify 
conserved domains within the i3 loop of the hM1 receptor that could play a role in 
agonist-dependent internalization.  The second component includes producing 
mutant receptors possessing changes of specific amino acids within each 
identified conserved domain.  The third component includes looking at the 
agonist-dependent internalization, signaling, and binding of each hM1 receptor 
mutant.  The signaling and binding assays ensure that the affect(s) of the 
mutation(s) on internalization are not because of changes in receptor function.  
 
Protein Motif 
Scan 
Receptor 
Mutagenesis 
Agonist-
dependent 
Internalization 
Assay 
Saturation 
Radioligand 
Binding Assay 
Phosphoinositide 
Hydrolysis 
Assay 
 
 
Figure 5.  Experimental approach to characterize a small domain in the i3 loop of 
the hM1 receptor. 
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CHAPTER II 
 
 
 
RESEARCH METHODS 
 
 
 
2.1  pCD-hM1 and Mutagenesis of the hM1 Receptor 
Mutant pCD-hM1 vectors were made using pCD-hM1 (generous gift of Dr. 
Tom Bonner at the NIMH), a modified Okayma-Berg expression vector 
possessing the hM1 receptor sequence (Bonner et al., 1997), and the 
QuikChange II Site-Directed Mutagenesis Kit.  Using the manufacturer’s 
instructions and various mutagenesis primers (see Table I ), several different 
point mutations were introduced into the M1 receptor domain 252-
PETPPGRCCRCCRA-265 (see Figure 6).  Mutagenesis of the hM1 receptor 
involved mutant strand synthesis, Dpn I digestion of the parental template, and 
transformation of XL1-Blue E. coli with the mutant plasmids.  All mutant pCD-hM1 
receptor constructs were sequenced at the OSU core facility (Stillwater, OK) to 
verify the presence of the mutation(s) before use and to ensure that no other 
mutations were acquired during PCR.  
The hM1 receptor sequence of pCD-hM1/T to A has an alanine in position 
254 instead of a threonine (Figure 6).  Alanine was substituted for cysteine in 
positions 259 and 260 of the hM1 receptor sequence of pCD-hM1/CC-AA 
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 (Figure 6) and in positions 262 and 263 of the hM1 receptor sequence of pCD-
hM1/2CC-AA (Figure 6).  In positions 259, 260, 262, and 263 of the hM1 receptor 
sequence of pCD-hM1/4CC-AA, and position 263 of pCD-hM1/2C-A (Figure 6), 
alanine was substituted for cysteine.  The hM1 receptor sequence of pCD-hM1 /P-
A has alanine in position 252 instead of proline (Figure 6). 
 
 
 
 
  WT   2 5 2 - P E T P P G R C C R C C R A - 2 6 5  
 
 T – A  2 5 2 - P E A P P G R C C R C C R A - 2 6 5  
 
 CC – AA    2 5 2 - P E T P P G R A A R C C R A - 2 6 5  
 
 2CC    2 5 2 - P E T P P G R C C R A A R A - 2 6 5  
 
 4CC   2 5 2 - P E T P P G R A A R A A R A - 2 6 5  
 
 2C - A  2 5 2 - P E T P P G R C C R C A R A - 2 6 5  
 
 P - A  2 5 2 - A E T P P G R C C R C C R A - 2 6 5  
 
 
 
 
 
 
 
 
 
Figure 6.  hM1/WT and mutant receptor amino acid sequence between residues 
252 - 265.  Using the QuikChange II site-directed mutagenesis kit and 
mutagenesis primers (see Table I ), point mutations were introduced at various 
positions in the i3 loop domain 252-PETPPGRCCRCCRA-265 exchanging 
alanine (bolded) for the WT amino acids. 
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Table І.  Mutagenesis Primers 
pCD-
hM1 
Mutant 
Primers Used 
T - A   
Forward 5’GAGGGCTCACCAGAGG1CTCCTCCAGGCCGCTGC 3’ 
Reverse 5’GCAGCGGCCTGGAGGAGC1CTCTGGTGAGCCCTC 3’ 
CC -AA   
Forward 5’GACTCCTCCAGGCCGCGCTGC1TCGCTGCTGCCGGGCC 3’
Reverse 5’GGCCCGGCAGCAGCGAGCAGC1GCGGCCTGGAGGAGTC 3’
2CC  
Forward 5’GGCCGCTGCTGTCGCGACGAT1CGGGCCCCCAGGCTG 3’
Reverse  5’CAGCCTGGGGGCCCGATCGTC1GCGACAGCAGCGGCC 3'
4CC   
Forward 5’ACTCCTCCAGGCCGCGACGACCGCGACGA1CCGGGCCCCCAGGCTG 3’ 
Reverse 5’CAGCCTGGGGGCCCGGTCGTCGCGGTCGTC1GCGGCCTGGAGGAGT 3’ 
2C - A   
Forward 5’ TGCTGTCGCTGCGC1CCGGGCCCCCAGG 3’
Reverse 5’CCTGGGGGCCCGGGC1GCAGCGACAGCA 3’
P - A   
Forward 5’GCTGAGGGCTCAG1CAGAGACTCCTCCAG 3’
Reverse 5’CTGGAGGAGTCTCTGC1TGAGCCCTCAGC 3’
 
1Bolded nucleotides represent the changes in the hM1/WT DNA sequence in the 
pCD-hM1 plasmid (Bonner et al., 1987). 
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2.2  Chinese Hamster Ovary (CHO) Cell Line Culture and Transfection 
The CHO-K1 cell line was derived as a subclone from the parental CHO 
cell line initiated from a biopsy of an ovary from an adult Chinese hamster by T.T. 
Puck in 1957 (Puck et al., 1958).  CHO-K1 cells were obtained from ATCC and 
were stored in the vapor phase of a Locator Jr. cryobiological storage system in 
aliquots (1 ml) at passage 2 in complete culture medium (F-12K, 10%FBS, 100 
units/ml penicillin G sodium, and 100 μg/ml streptomycin sulfate) and 5% DMSO.  
Frozen cells were thawed at 37°C and revived in complete culture medium.  After 
revival, CHO-K1 cells were maintained in 75 cm2 flasks in complete culture 
medium in a humidified incubator at 37°C and 5% CO2.   
For agonist-dependent internalization, phosphoinositide hydrolysis, and 
saturation ligand binding assays, CHO-K1 cells were trypsinized and seeded in a 
24-well plate format at cell density of 1.75 x 105 cells per well in 500 μl 
transfection medium (F-12K, 10% FBS) and incubated in a humidified incubator 
at 37°C and 5% CO2 for 24 hours.  Cells were transfected using Lipofectamine 
2000 according to the manufacturers’ protocol.  Briefly, 0.8 μg/well plasmid DNA 
(19.2 μg/plate) was incubated with 50 μl/well Opti-MEM I (1,200 μl/plate) for 5 
minutes at room temperature in a 15-ml conical tube.  Lipofectamine 2000 (48 
μl/plate) was incubated in a separate tube with 50 μl/well Opti-MEM I (1,200 
μl/plate) for 5 minutes at room temperature.  The plasmid DNA and lipofectamine 
mixtures were combined into a single tube, mixed gently, and incubated for 20 
minutes at room temperature allowing DNA/Lipid complexes to form.  Complexes 
(100 μl/well) were added to each well of the 24-well CHO-K1 plate, rocked gently, 
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and placed into a humidified incubator set at 37°C in a 5% CO2 atmosphere.  
After 6 hours of incubation, the media containing DNA/Lipid complexes was 
replaced with 500 μl of fresh transfection medium.  Cells were incubated an 
additional 18 hours in a humidified incubator set at 37°C in a 5% CO2 
atmosphere. 
 
2.3  Agonist-Dependent Internalization Assays 
 To determine the degree of WT and mutant hM1 receptor internalization in 
response to agonist, the membrane impermeable muscarinic receptor selective 
radioligand [3H]NMS was used to determine the amount of plasma membrane 
expressed receptor before and after incubation with carbachol (a muscarinic 
receptor selective agonist).  Transiently transfected CHO-K1 cells were 
incubated with 1 mM carbachol in 500 μl of F-12K medium without FBS, for up to 
4 hours at 37°C in 5% CO2 atmosphere.  Intact whole cell binding assays were 
then performed.  Cells were rapidly and gently washed twice on ice with 500 μl 
ice-cold PBS (11.9 mM phosphates, 137 mM NaCl, 2.7 mM KCl).  The intact cells 
were then incubated for 1 hour at 4°C with 1.6 nM [3H]NMS in the absence (total 
binding) or presence (nonspecific binding) of 0.1 μM of atropine in 500 μl binding 
buffer (25 mM HEPES, 113 mM NaCl, 6 mM dextrose, 3 mM CaCl2, 3 mM KCl, 2 
mM MgSO4, 1 mM NaH2PO4, pH 7.4).  Following incubation, each well was 
rapidly, and gently washed twice on ice with ice-cold PBS (1 ml/wash), then 
incubated with 0.25 N NaOH (500 μl) for 30 minutes at room temperature.  2.5 N 
HCl (70 μl) was added, and neutralized extracts were then transferred from each 
22 
well of the plate into individual 7-ml scintillation vials.  Scintiverse (5 ml) was 
added and the radioactivity was determined using a LS 6500 scintillation counter 
(Beckman). 
 Average total protein was determined every experiment for each hM1 
receptor construct characterized.  Briefly, 3 wells of a 24-well plate were seeded 
with CHO-K1 cells and transiently transfected with WT or mutant hM1 receptor 
constructs as described in section 2.2.  On the day of the experiment, cells were 
washed two times with 500 μl of mannitol wash buffer (0.29 M mannitol, 0.01 M 
Tris, 0.5 mM Ca(NO3)2 ,pH 7.4), then incubated with 1 N NaOH (1 ml) for 15 
minutes at room temperature as described previously (Goldschmidt and 
Kimelberg, 1989).  Cells were then sonicated for 1 minute at room temperature 
and 1 N HCL (100 μl) was added to neutralize a 100 μl aliquot of cell extract.  
Bicinchoninic acid (BCA ) regent (1 ml) was added as described by Goldschmidt 
and Kimelberg (1989).  The remainder of the assay was conducted according to 
Pierce (Rockford, IL) manufacture protocol. 
 
2.4  Phosphoinositide Hydrolysis Assays 
 To determine whether mutant hM1 receptors could still elicit 
phosphatidylinositol metabolism when exposed to agonist, CHO-K1 cells 
transiently expressing the hM1/WT and mutant receptors were used in 
phosphoinositide hydrolysis assays.  Transiently transfected CHO-K1 cells were 
incubated with 0.2 μM [3H]myo-inositol in 500 μl F-12K medium.  After 18 hours 
of incubation in a humidified incubator at 37°C and 5% CO2, cells were washed 
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twice with 500 μl F-12K medium with a 10 minute incubation at 37°C and 5% 
CO2, in between washes.  For a final wash, cells were washed with 300 μl F-12K 
medium containing 10 mM LiCl and incubated for 10 minutes at 37°C and 5% 
CO2.  The washed cells were then incubated with 300 μl of F-12K medium 
containing 10 mM LiCl and geometrically spaced concentrations of carbachol 
(0.5 log unit) for 30 minutes in a humidified incubator at 37°C and 5% CO2.  After 
incubation, the media was aspirated from each well and cells were incubated for 
15 minutes on ice in 200 μl of ice-cold 5% PCA.  To each well 365 μl (volume 
dependent on titration values of individual batch) of 0.525 M KOH in 10 mM Tris-
HCl was added and the cells were incubated for an additional 15 minutes on ice.  
The neutralized PCA extracts were transferred into individual 1.5 ml 
microcentrifuge tubes and each well was washed with 400 μl of 25 mM Tris-HCl, 
pH 7.4.  Each wash was added to its corresponding microcentrifuge tube and the 
tubes were centrifuged at 3000 x g for 10 minutes in a microcentrifuge 5415 D 
(Eppendorf) to pellet any cellular debris.  The supernatant was transferred into 
individual glass test tubes (16 x 100 mm) containing 2 ml of 25 mM Tris-HCl, pH 
7.4 and mixed.  The solution from each tube was applied to individual 1 ml 
Dowex AG 1-X8 (formate form, 100-200 mesh) columns.  Columns were washed 
4 times with 4 ml deionized ultra filtered water and [3H]inositolphosphates were 
eluted using 2.5 ml of solution containing 1 M ammonium formate and 0.1 M 
formic acid into 25 ml scintillation vials.  To each vial, 20 ml of Scintiverse was 
added and radioactivity was counted using a LS 6500 scintillation counter. 
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2.5  Saturation Radioligand Binding Assays 
 To determine whether the various amino acid substitutions we made 
affected the affinity of the receptor for ligands or the plasma membrane 
expression of the receptor, we conducted radioligand binding assays with 
[3H]NMS.  Using this approach, we were able to obtain an estimate of the 
equilibrium dissociation constant (KD) for each receptor mutant and determine the 
maximal number of binding sites (Bmax) expressed at the plasma membrane.  As 
mentioned in section 2.3, the [3H]NMS is membrane impermeable, so it is a good 
radioligand for detecting whether there is an affect of the mutations on plasma 
membrane expression of the receptor.   
Transiently transfected CHO-K1 cells were rapidly and gently washed 
twice on ice with 500 μl per well ice-cold PBS.  Intact cells were then incubated at 
4°C for 1 hour with geometrically spaced concentrations of [3H]NMS (0.33 log 
unit) in the absence (total binding) or presence (nonspecific binding) of 0.1 μM of 
atropine in 500 μl binding buffer.  Following incubation, cells from each well were 
rapidly and gently washed twice on ice with ice-cold PBS (1 ml/wash), then 
incubated with 0.25 N NaOH (500 μl) for 30 minutes at room temperature.  70 μl 
of 2.5 N HCl was added and the neutralized extracts were transferred from each 
well of the plate into individual 7-ml scintillation vials.  Scintiverse (5 ml) was 
added and the radioactivity was determined using a LS 6500 scintillation counter. 
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2.6  Mathematical Analysis 
 Specific [3H]NMS binding was calculated for each concentration of 
[3H]NMS used in radioligand binding assays (see section 2.5) and each time 
point in agonist-dependent internalization assays (see section 2.3) using 
equation 1. 
 
BindingcNonspecifiBindingTotalBindingSpecific   -     =      eq. 1 
 
Mole specific binding was calculated using equation 2.  
 
))((
)(
NX
dpmBindingSpecificBindingSpecificMole =        eq. 2 
 
In equation 2, X denotes the conversion factor for dpm to Ci (1 Ci = 2.22 x 1012  
dpm).  N denotes the specific activity of [3H]NMS, which in this study was either 
81 or 82 Ci/mmol.  Femtamole specific binding was calculated using equation 3.  
 
( )molfmolBindingSpecificMoleBindingSpecificFmol / 10  1         15××=    eq. 3 
 
The percent of maximal specific [3H]NMS binding was calculated for each time 
point in the carbachol-induced internalization assay by dividing the fmol specific 
binding at time point 0 hour by the fmol specific binding at time point 0.5, 1, 2, 3. 
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or 4 hour and multiplying by 100.  Non linear analysis for PI assays and 
saturation binding assays was calculated using equation 4. 
 
 ( )( )nH]NMS[EC KD -y  /1010 1 minmax  min 350 logor  log++=                                                  eq. 4 
 
In this equation, min denotes minimum specific [3H]NMS binding, max denotes 
BBmax in binding assays or Emax in PI assays, and n denotes the hill coefficient 
(Bowen and Jerman, 1995).  Mole specific binding per mg protein was calculated 
by dividing the mole specific [ H]NMS binding by the mean mg protein 
determined in the BCA assay described in section 2.3.   
3
 
2.6.1  Statistical Analysis 
Data from the agonist-dependent internalization assay was analyzed by 
two-way ANOVA, to test for overall main effect or effect of mutation, time, or 
relationship between time and mutation, followed by a Bonferroni analysis 
corrected for multiple comparisons.  A one-way ANOVA, to test for effect of 
mutation, with Bonferroni post-test was used to analyze the data from the 
saturation radioligand binding assay, and the phosphoinositide hydrolysis assay.  
p < 0.05 was considered statistically significant for all tests.  ANOVA analysis 
was performed using GraphPad-Prism software, version 4.03 (GraphPad, San 
Diego, CA). 
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2.7  Materials 
All reagents and labware were obtained from Fisher Scientific (USA) 
except for the following:  The QuikChange Mutagenesis Kit was purchased from 
Stratagene (La Jolla, CA).  CHO-K1 cells, FBS, and F-12 medium were 
purchased from ATCC (Manassas, VA).  Lipofectamine 2000, penicillin G 
sodium/Streptomycin sulfate, primers for mutagenesis, and Opti-Mem 1 were 
obtained from Invitrogen (Carlsbad, CA).  DMSO, carbachol, atropine, HEPES, 
LiCl, PCA, ammonium formate, formic acid, were purchased from Sigma (St. 
Louis, MO).  Radioactive reagents, [3H]NMS and [3H]myo-inositol, were 
purchased from PerkinElmer Life and Analytical Science (Boston, MA).  BCA 
reagent kit was manufactured by Pierce (Rockford, Il.).  Microcentrifuge 5415D 
was manufactured by Eppendorf (Westbury, NY).  Dowex AG 1-X8 was 
purchased from Bio-Rad (Hercules, CA).  The LS 6500 scintillation counter was 
manufactured by Beckman Coulter (Fullerton, CA). 
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CHAPTER III 
 
 
 
RESULTS 
 
 
3.1  General Overview of Results 
 
 Previously in our laboratory, a small 8 amino acid deletion in the third 
intracellular loop was found to decrease the extent of agonist-induced 
internalization of hM1 receptors (unpublished observation) and is shown in Figure 
3.  Characterization of this small 8 amino acid domain prompted investigating the 
amino acids within and surrounding the domain to identify all amino acids that 
may play a role in agonist-dependent internalization.  Once the amino acid(s) that 
potentially play a functional role in the domain were identified, mutants were then 
made by replacing the existing amino acid(s) with alanine to determine whether 
the amino acids were involved in the previously seen affect of deleting aa 254-
261 on agonist-induced internalization.  The mutant hM1 receptors were then 
compared to hM1/WT receptors in relevant assays (Figure 5).  The agonist-
dependent internalization assay was used to identify the amino acid(s) that play a 
role in internalization.  Saturation radioligand binding assays were used to 
determine the affinity of the ligand for the receptors.  Phosphoinositide hydrolysis 
assays were used to determine whether or not the mutant receptor elicits 
phosphoinositide hydrolysis to agonist. 
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3.2  Identification of Protein Sequence Motifs Within or Overlapping with a 
Small Domain in the I3 Loop of hM1 Receptors 
 
 Utilizing a web-based protein motif scan program (http://scansite.mit.edu), 
the 8 amino acid domain found previously and surrounding amino acids were 
searched for consensus sequences of known biological function. 
 The protein motif scan, which identifies signatures of protein families, 
retrieves all of the respective family members from the sequence and allows 
classification of an unknown sequence based on the homology of known proteins 
(Bork and Gibson, 1996; Bork and Koonin, 1996).    If the sequence motif 
matches 100%, the score is 0.00 and as the sequence diverges from the match, 
the score increases.  The percentile value given for a motif scan is calculated 
from the vertebrate section of the Swiss-Prot reference database (Obenauer et 
al., 2003).   A high stringency scan identifies the sequence motifs that match in 
the best 0.2% of all sites available where the medium stringency scan highlights 
the sequence motifs that match in the best 1% of all sites available.  Two 
potential domains of known function were found in the i3 loop of hM1 receptors 
using this approach.  These domains were in close proximity to the 8 amino acid 
domain previously identified. 
 The first domain of known function, found in a medium stringency motif 
scan, was a putative amphiphysin SH3 binding domain (245-
QPGAEGSPETPPGRC-259), with a score of 0.5784 in the 0.913 percentile.  The 
second domain of known function, found with a high stringency motif scan, was a 
putative proline-dependent serine/threonine kinase (Pro_ST_Kin) Cdc 2 kinase 
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phosphorylation site (247-GAEGSPETPPGRCCR-261) with a score of 0.4276 
and 0.147 percentile. 
 The 8 amino acid domain and adjacent amino acids contain several 
cysteine residues (254-TPPGRCCR-262 + 263-CCR-265).  Disulfide bonds can 
be formed between the side chains of adjacent cysteines (Carugo et al., 2003), 
raising the possibility that vicinal (adjacent) disulfide linkages may play a part in 
the affect on internalization seen previously.  Extracellular cysteines forming 
disulfide bridges have been shown to participate in the formation of disulfide-
linked M3 receptor dimers (Zeng and Wess, 2000), but studies on intracellular 
adjacent cysteines have not been addressed.  Also, vicinal disulfide bonds can 
play a structural role in the protein backbone conformation (Carugo et al., 2003).  
Conformational changes, because of expression of mutant cysteine to alanine 
hM1 receptors, could possibly alter an unknown mechanism in agonist-dependent 
internalization. 
 The hM1 receptor was mutagenized based on the information from the 
protein motif scan and putative vicinal disulfide linkages.  Alanine amino acid 
residues were substituted for amino acid residues to eradicate both known 
consensus sequences from the motif scan and alanine was substituted for 
various patterns of the cysteines (Figure 6). 
 
3.3  General Overview of the Agonist-Dependent Internalization Assay  
 To determine what effect each of the different mutations has on the 
internalization elicited by the muscarinic receptor selective agonist carbachol, 
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agonist-dependent internalization assays were performed.  Agonist activation of 
muscarinic receptors is known to cause a rapid redistribution (internalization) of 
receptors from the plasma membrane to an intracellular compartment (Koenig 
and Edwardson, 1997), and in a previous investigation, the agonist-dependent 
internalization of hM1 receptors was determined to require a domain or domains 
in the third cytoplasmic loop (i3) of the receptor (Lameh et al., 1992).  This was 
consistent with the recently identified small domain (252-265) in the hM1 receptor 
i3 loop that was shown to affect agonist-induced internalization of the receptor 
when deleted (unpublished observations).  To completely characterize the role 
this small domain plays in the agonist-induced internalization of hM1 receptors, 
CHO-K1 cells, which do not express muscarinic receptors, were transfected with 
various mutant pCD-hM1 receptor constructs possessing different amino acid 
substitutions (see Figure 6).  The transfected cells were allowed to produce and 
express receptor for 24 hours prior to treatment with carbachol (1 mM) for time 
periods up to 4 hours.  The concentration of carbachol used in this investigation 
was obtained from previous in vitro studies (Lameh et al., 1992; Lee et al., 1998; 
Maeda et al., 1990; Moro et al., 1993; Tolbert and Lameh, 1996).  Measurement 
of plasma membrane expressed receptors before and after carbachol treatment 
was accomplished using an intact whole cell binding assay with the membrane 
impermeable antagonist [3H]NMS.  Like carbachol, [3H]NMS is selective for 
muscarinic receptors.  Percent of maximal binding was calculated by dividing the 
fmol specific binding at a given time point with agonist stimulation by the fmol 
specific binding at the zero time point (no agonist).  This internal standardization 
32 
allowed the hM1/WT data previously obtained in the laboratory, using the same 
protocol as described in the “Research Methods” section, to be compared to 
current data.  
 
3.4  General Overview of Saturation Radioligand Binding Assay 
 Saturation radioligand binding assays allow for the measurement of the 
maximal number of receptor binding sites (Bmax), and the equilibrium dissociation 
constant (KD) of a ligand.  The Bmax and KD are valuable in receptor classification, 
and interpretations on possible changes in receptor structure that affect affinity.  
The emphasis of this investigation was to determine if the effects of various 
mutations in the i3 loop of hM1 receptors on internalization were due to changes 
in affinity of the ligand for the receptor. 
 The affinity of a ligand for a receptor is defined by the interaction strength 
between the two and is quantified by the equilibrium dissociation constant.  
Distinctively, the KD is the concentration of ligand that binds to 50% of the total 
receptor population.  Correspondingly, the higher the KD value, the lower the 
affinity of the ligand has for the receptor because it takes a higher concentration 
of ligand to bind 50% of the receptors.  The maximal number of binding sites 
(Bmax), is defined at theoretically infinite ligand concentrations and its accuracy is 
proportional to the maximal levels of radioligand that can be used in the 
experiment to determine receptor density (Kenakin, 2003).  In this experiment, 
[3H]NMS was used to define Bmax of all the hM1 receptor constructs 
characterized.  [3H]NMS is a high affinity radioligand for hM1 (pKD = 9.57 ± 0.07).  
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Therefore, it was possible to obtain ~ 100% occupancy and Bmax could be 
estimated from saturating radioligand binding assays using equation 5 (page 26). 
 
3.5  General Overview of Phosphoinositide Hydrolysis Assay 
 hM1 receptors transduce agonist binding by activating G proteins to 
regulate ion channel activity and/or generate second messengers by utilizing the 
phosphoinositide (PI) system.  At basal state conditions, G proteins exist in cell 
membranes as heterotrimers composed of single α, β, and γ subunits, with GDP 
bound to the α subunit  (Birnbaumer et al., 1990; Siegal et al., 1999).  When an 
agonist binds the hM1 receptor, the receptor physically associates with the α 
subunit.  This interaction promotes the disassociation of GDP from the α subunit 
and GTP can bind in its place.  The α subunit with GTP disassociates from the βγ 
subunits, and regulates an effector protein, phospholipase C (PLC).  Hydrolysis 
of phosphatidylinositol-4,5-bisphosphate (PIP2) by PLC yields two products: 1,2-
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3).  Incubation of hM1 
transfected CHO-K1 cells with [3H]inositol 24 hours before performing the assay 
allows incorporation of [3H] into PIP2.  Therefore, to determine whether mutant 
hM1 receptors could still elicit phosphatidylinositol metabolism when exposed to 
agonist, [3H]IP3, which does not recycle in the presence of 10 mM LiCl, was 
assayed and counted with a scintillation counter.  Measurement of potency is 
defined using the EC50, which is the molar concentration of an agonist required to 
produce 50% of the maximal response to the agonist.  
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3.6  Mutant Receptors hM1/T-A and hM1/P-A 
 To determine whether the effect on internalization, seen previously when 
the small domain (252-265) was deleted in the i3 loop of hM1 receptors, was a 
consequence of disrupting either a putative SH3 binding domain or a proline 
dependent serine/threonine kinase site, mutations at critical positions for each 
consensus sequence were made.   To disrupt the putative SH3 binding domain, 
an alanine was substituted at position 252 for proline (hM1/P-A, see Figure 6) 
and alanine was substituted at position 254 for threonine (hM1/T-A, see Figure 6) 
to disrupt the putative kinase site.  Internalization, saturation binding and 
phosphoinositide hydrolysis assays were then performed. 
 
3.6.1  Internalization of hM1/T-A and hM1/P-A Receptor Mutants  
 Figure 7 depicts the effects of carbachol (1 mM) treatment on the plasma 
membrane expression of hM1/T-A and hM1/P-A receptor mutants compared to 
wild-type hM1 receptors.  Approximately 40% of maximal specific [3H]NMS 
binding was observed for hM1/WT, T-A and P-A during the 4 hour carbachol 
treatment, suggesting that neither mutation had an effect on agonist-induced 
internalization (Table II).  The percent internalization was very similar when 
comparing these mutant receptors to WT receptors (Table III).  In fact, no 
significant differences (F2,66 = 0.86; p > 0.05) were observed at each of the time 
points considered (Table II, Figure 7) when using a two-way ANOVA with post 
hoc Bonferroni post-test with selective comparisons.  Therefore, the effect on 
agonist-dependent internalization seen previously with the hM1/8 aa del mutant 
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receptor, does not appear to be a result of disrupting either the putative SH3 
domain or serine/threonine kinase site. 
 
 
 
 
Figure 7.  Carbachol-dependent internalization of hM1/T-A and hM1/P-A 
receptors.  The extent of mutant hM1/T-A and hM1/P-A receptor internalization in 
response to the agonist carbachol (1 mM) showed no significant difference from 
the hM1/WT receptor.  CHO-K1 cells transiently expressing hM1/T-A, or hM1/P-A 
receptors were incubated with the agonist carbachol (1 mM) for up to 4 hr at 
37°C in an atmosphere of 5% CO2 before conducting intact whole cell [3H]NMS 
binding assays (see “Research Methods”).  The mutants hM1/P-A (z), hM1/T-A 
(), and hM1/WT () are shown.  Each series of data points represents an 
experiment conducted in triplicate either 3 (hM1/WT, hM1/P-A), or 8 times (hM1/T-
A), ± S.E.M.   
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Table II. Summary of hM1/WT, T-A and P-A Receptor [3H]NMS Binding  
 
    Specific [3H]NMS Binding (% of maximal) 
     For Receptor Constructs   
Time of 
Carbachol 
(1mM) 
Treatment  
hM1/WT1 hM1/T-A2 hM1/P-A1
0.5 hr 77.1 ± 4.6 79.2 ± 3.7 69.7 ± 3.7 
1 hr 67.8 ± 5.4 76.9 ± 4.0 69.4 ± 3.2 
2 hr 55.7 ± 3.7 58.4 ± 3.2 55.6 ± 3.4 
3 hr 48.2 ± 3.1 47 ± 3.0 49.3 ± 1.6 
4 hr 36.6 ± 8.7 40.7 ± 2.2 42.9 ± 1.4 
 
 
 
 
hM1/T-A and P-A receptor mutants internalize in a manner consistent with 
hM1/WT receptors when incubated with carbachol for up to 4 hours.  Data 
presented in table represents data points in Figure 7. 
 
1 Each time point data represents the mean ± S.E.M. of 3 experiments conducted 
 in triplicate. 
2 Each time point data represents the mean ± S.E.M. of 8 experiments conducted 
 in triplicate. 
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Table III. Percent Internalization of hM1/WT, T-A, and P-A at Given Time 
Points  
 
 
          % Internalization 
hM1 Receptor 
Constructs 
0.5 hr 1.0 hr 2.0 hr 3.0 hr 4.0 hr 
T-A 20.8 23.1 41.6 53.0 59.3 
P-A 30.3 30.6 44.4 50.7 57.1 
WT 22.9 32.2 44.3 50.7 57.1 
 
 
Data presented in Table III represents the percent internalization of hM1 
receptors based on the agonist-dependent internalization assays with [3H]NMS. 
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3.6.2  hM1/T-A and hM1/P-A Dissociation Equilibrium Constant 
 
 To determine if the disruption of either the putative SH3 binding domain or 
the proline dependent serine/threonine kinase site affected binding of the ligand 
to the receptor, CHO-K1 cells were transiently transfected with hM1/T-A and 
hM1/P-A and then incubated with geometrically spaced (0.33 log unit) 
concentrations of [3H]NMS as described in “Research Methods”.  Figure 8 
depicts the nonlinear curve fitted plot of hM1/T-A and P-A compared to hM1/WT.  
The affinity or strength of interaction of the ligand to bind to the receptor was 
decreased significantly (F2,8 = 17.84, p < 0.01) between the hM1/WT and hM1/T-A 
and P-A.  The pKD for hM1/WT was 9.57± 0.07 and the pKD for hM1/T-A and P-A 
was 9.22 ± 0.04 and 9.23 ± 0.04 respectively (Table IV).  Even though the affinity 
of the ligand for the mutant receptors was lower, the ligand was not prevented 
from binding.  This would suggest that the putative SH3 binding domain or 
proline dependent serine/threonine kinase site is not responsible for the 
decreased extent of agonist-dependent internalization observed for hM1/8 aa del. 
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Figure 8.  Specific [3H]NMS binding comparison of hM1/WT, hM1/T-A, and 
hM1/P-A receptors.  CHO cells expressing either of the following hM1 
receptors: hM1/ (),hM1/T-A (), or hM1/ P-A (z), were incubated with 
geometrically spaced (0.33 log unit) concentrations of [3H]NMS as 
described in “Research Methods”.  Each data point represents the mean ± 
the S.E.M. of 3 experiments conducted in triplicate. 
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3.6.3  Maximal Number of Binding Sites (BBmax) for hM1/WT and hM1/T-A and 
P-A Mutant Receptors 
 
 BBmax describes the maximal number of binding sites available on the cell 
surface and can be defined when using saturating concentrations of the 
membrane impermeable [ H]NMS.  B3 max indicates the amount of receptor density 
as molar concentration of receptors per milligram protein. The hM1/T-A Bmax 
values (685.80 ± 49.0) were similar to hM1/WT (643.98 ± 69.9).  There was a 
significant mutation dependent increase (F2,8 = 7.687, p < 0.05) in Bmax between 
hM1/P-A and hM1/WT (Table IV).  
 
Table IV.  Mutant Receptors hM1/T-A and P-A pKD, Bmax , and Hill Slope Data 
From Saturation Binding Assay1
 
hM1 Receptor 
Constructs 
pKD BBmax Hill Slope 
 WT () 9.57 ± 0.07 643.98 ± 69.9 1.48 ± 0.20 
T-A () 9.28 ± 0.05 ¾¾ 685.80 ± 49.0 1.47 ± 0.05 
P-A (z) 9.23 ± 0.04 ¾¾ 916.50 ± 33.5 ¾ 1.77 ± 0.11 
 
1Data presented in table represents data collected from saturation radioligand 
binding assays (Figure 8).  The KD (equilibrium dissociation constant), Bmax 
(maximal number of binding sites available) and Hill slope was estimated using 
nonlinear regression as described previously by Bowen and Jerman, 1995.  
Significant difference is denoted (¾ = p < 0.05 and ¾¾ = p < 0.01) and was 
determined using an one-way ANOVA with post hoc Bonferroni’s multiple 
comparison test. 
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3.6.4  Agonist Potency of hM1/T-A and hM1/P-A Mutant Receptors 
 To determine if hM1/T-A and P-A receptors could still elicit 
phosphatidylinositol metabolism when exposed to agonist, CHO-K1 cells were 
transiently transfected with mutant receptor and phosphoinositide hydrolysis (PI) 
assays were performed as described in “Research Methods”.   
 The concentration of the agonist carbachol that produced 50% of the 
maximal response for mutant hM1/T-A (pEC50 = 5.57 ± 0.05) and hM1/P-A (pEC50 
= 5.46 ± 0.03) was similar to hM1/WT (pEC50 = 5.34 ± 0.10).  The mutations did 
not affect the potency of phosphoinositide hydrolysis elicited to carbachol (Figure 
9), but there was a 1.6-fold increase in maximal response for both hM1/T-A and 
P-A compared to hM1/WT. 
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Figure 9.  Comparison of the phosphoinositide response of hM1/WT, hM1/T-A 
and hM1/P-A receptors.  hM1/T-A () and hM1/P-A (z) mutations did not affect 
the potency of PI hydrolysis elicited to the agonist carbachol.  CHO-K1 cells 
transiently expressing hM1/T-A, or hM1/P-A receptors were incubated with 
[3H]myo-inositol (0.2 μM) 24 hours before performing phosphoinositide hydrolysis 
assays (see “Research Methods”).  Each data point represents an experiment 
conducted in triplicate either 3 or 4 times ± the S.E.M. 
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3.7  Characterization of Mutant Receptors hM1/2C-A, hM1/2CC, hM1/4CC and 
 hM1/CC-AA 
 
 To determine whether the effect on internalization, seen previously when 
the small domain (252-265) was deleted in the i3 loop of hM1 receptors, was due 
to vicinal disulfide bonds or other effects of cysteine residues, mutations 
substituting alanine for various cysteines were made.  Vicinal disulfide bonds 
may form between adjacent cysteine residues, so mutations changing the 
cysteines 259 and 260 (hM1/CC-AA), 261 and 262 (hM1/2CC), and 259, 260, 
261, and 262 (hM1/4CC), and 262 (hM1/2C-A) to alanine(s) were made (Figure 
6). 
 
3.7.1  Internalization of Cysteine to Alanine Receptor Mutants   
 Figure 10 summarizes the effects of carbachol (1 mM) on the plasma 
membrane expression of hM1/CC-AA, hM1/2CC, hM1/4CC, hM1/2C-A receptor 
mutants compared to hM1/WT.  In general, the cysteine to alanine mutations had 
a significant (F4,96 = 99.04, p < 0.0001) affect on the agonist-dependent 
internalization of mutant receptor when compared to WT.  
 Multiple comparisons between mutated receptors were performed using 
Bonferroni’s multiple comparison tests.  Among the cysteine to alanine mutations 
tested the least responsive to carbachol-induced internalization were the 
hM1/4CC and hM1/2CC receptors.  These receptors are very similar to each 
other.  The 2CC and 4CC receptors are both mutated at amino acids 262 and 
263 (Figure 6).  Compared to the hM1/WT receptor starting at time point 1 hour 
thru the 4 hour time point there was significant difference (p < 0.001) from both 
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the hM1/4CC and hM1/2CC receptors in the amount of specific [3H]NMS binding 
(Table V).      
 
Figure 10.  Carbachol-dependent internalization of cysteine to alanine mutant 
receptors.  The extent of mutant hM1 receptor internalization varies depending 
upon the position of the mutation within the i3 loop domain 252-265 (Figure 6).  
CHO-K1 cells transiently expressing various cysteine to alanine mutant hM1 
receptors were incubated with the agonist carbachol (1 mM) for up to 4 hours at 
37°C in an atmosphere of 5% CO2 before conducting whole cell [3H]NMS binding 
assays (see “Research Methods”).  The hM1/WT (), and mutants hM1/2C to A 
(▲), hM1/CC-AA (), hM1/2CC (U), hM1/4CC (V), are shown.  Each data series 
represents an experiment conducted in triplicate either 8 (hM1/CC-AA), 4 
(hM1/4CC), or 3 times (hM1/WT, hM1/2C-A, and hM1/2CC,), ± the S.E.M.  
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 hM1/2C-A internalization in response to the agonist carbachol showed no 
significant difference from the hM1/WT receptor for the time points 0.5 hour, 1 
hour, 2 hour, however the 3 hour and 4 hour time point did show significant 
decrease (p < 0.05 and p < 0.001 respectively) in extent of internalization from 
hM1/WT (Table V).  hM1/CC-AA showed significant decrease (p < 0.001) in 
extent of internalization from hM1/WT for all time points (Table V).  Both hM1/2C-
A and hM1/CC-AA displayed partially deficient internalization when compared to 
hM1/4CC and 2CC (Figure 10).  The hM1/CC-AA mutant receptor is very similar 
in percent internalization to the mutants hM1/4CC and 2CC at the 0.5 hour, 1 
hour, and 2 hour time point.  However, there was a 3.2-fold increase in 
internalization of the hM1/CC-AA receptor at the 3 hour time point and ~2.3-fold 
increase at the 4 hour time point when compared to hM1/4CC and 2CC.  It is 
interesting to point out that the mutant receptor hM1/CC-AA is similar in sequence 
to the hM1/4CC because they are both mutated at amino acids 259 and 260 
(Figure 6).  The decrease in [3H]NMS binding is not as extensive as the hM1/WT 
receptor at the 3 hour time point where internalization of hM1/CC-AA is 1.6-fold 
less than WT, and 1.4-fold less at the 4 hour time point (Table VI).  Similarly, the 
hM1/2C-A receptor does not internalize to the extent of the hM1/WT at time point 
3 hour (1.3-fold less) and 4 hour (1.3-fold less).  It is interesting to note the 3.8-
fold greater internalization of hM1/2C-A at the 0.5 hour time point when compared 
to hM1/CC-AA but at the 4 hour time point there is only 1.1-fold difference in 
internalization (Table VI) .  
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Table V.  Summary of hM1/WT, 4CC-AA, 2CC-AA, 2C-A, and CC-AA    
  Receptor [3H]NMS Binding 
 
    Specific [3H]NMS Binding (% of maximal) 
     For Receptor Constructs1
 
Time of 
Carbachol 
(1mM) 
Treatment 
hM1/WT2 hM1/4CC2 hM1/2CC2 hM1/2C-A2 hM1/CC-AA3
0.5 hr 77.1 ± 4.6 90.7 ± 2.2¾ 91.6 ± 2.2¾ 71.9 ± 1.2 93.2 ± 2.1¾¾
1 hr 67.8 ± 5.4 100 ± 2.8¾¾ 100 ± 4.5¾¾ 78 ± 1.0 96.5 ± 3.3¾¾
2 hr 55.7 ± 3.7 89.1 ± 1.1¾¾ 89.7 ± 2.7¾¾ 68.1 ± 1.7 81.5 ± 2.3¾¾
3 hr 48.2± 3.1 90.4 ± 2.7¾¾ 90.4  ± 1.0¾¾ 62.4 ± 1.2¾ 69.2 ± 2.3¾¾
4 hr 36.6 ± 8.7 83.9 ± 4.2¾¾ 81.7 ± 0.9¾¾ 55.9 ± 1.9¾¾ 60.1 ± 1.5¾¾
 
 
 
1Significant differences were determined by using a two way ANOVA with post 
hoc Bonferroni post-test selective comparisons between hM1 mutants and 
hM1/WT for each time point.  ¾ denotes significant difference (p<0.05), and ¾¾ 
denotes significant difference (p < 0.001) from hM1/WT.  Data presented in table 
represents data points from Figure 10. 
 
 
2 Each data time point represents the mean ± S.E.M. of 3 experiments conducted 
 in triplicate. 
3 Each data time point represents the mean ± S.E.M. of 8 experiments conducted 
 in triplicate. 
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Table VI.  Percent Internalization of hM1 Cysteine to Alanine Mutant   
       Receptors at Given Time Points1
 
          % Internalization at the Specified Incubation Time 
hM1 Receptor 
Constructs 
0.5 hr 1.0 hr 2.0 hr 3.0 hr 4.0 hr 
4CC 9.3 0.0 10.9 9.6 16.1 
2CC 8.4 0.0 10.3 9.6 18.3 
2C-A 25.5 22.5 32.9 38.2 45.0 
CC-AA 6.7 3.5 18.5 30.8 39.9 
WT 22.9 32.2 44.3 50.7 57.1 
 
1Data presented in table represents the percent internalization of hM1 receptors 
based on the agonist-dependent internalization assay with [3H]NMS.   
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3.7.2  hM1/2C-A, hM1/2CC, hM1/4CC, hM1/CC-AA and hM1/WT Dissociation 
Equilibrium Constant 
 
 To measure the equilibrium dissociation constant (KD) to determine if 
changing the cysteine residues to alanines effected the binding of the ligand to 
the receptor compared to hM1/WT, CHO-K1 cells were transiently transfected 
with hM1/2C-A, hM1/2CC, hM1/4CC, and hM1/CC-AA.  Transfected cells were 
then incubated with geometrically spaced (0.33 log unit) concentrations of 
[3H]NMS as described in “Research Methods”.   
 In general, the cysteine to alanine mutant receptors pKD values were 
significantly (F5,19  = 12.33, p < 0.0001) decreased compared to hM1/WT using an 
one way ANOVA.  Figure 11 depicts the nonlinear curve fitted plot of the mutant 
hM1 receptors compared to hM1/WT.  The pKD values for hM1/2CC, 4CC, and 
CC-AA, were decreased (hM1/2CC and 4CC p < 0.001, hM1/CC-AA p < 0.01) 
compared to hM1/WT, and mutant receptors had a lower affinity (4.2-fold, 4.5-
fold, 3.4-fold, respectively) of the ligand for the receptor (Table VII).  hM1/2C-A 
pKD value was not significantly different than hM1/WT, but did have a 1.9-fold 
lower affinity of the ligand for the receptor (Table VII). 
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Figure 11.  Cysteine to alanine mutant receptor comparison of specific [3H]NMS 
binding to hM1/WT receptor.  CHO-K1 cells transiently transfected with one of the 
following, hM1/2C-A (▲), hM1/2CC(U), hM1/4CC(V), hM1/CC-AA(), 
hM1/WT(), were incubated with geometrically spaced (0.33 log units) 
concentrations of [3H]NMS as described in “Research Methods”.  Each data point 
represents the mean ± the S.E.M. of 3 experiments conducted in triplicate. 
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Table VII.  pKD, Bmax , and Hill Slope Data From Saturation Binding Assay of  
        hM1 Cysteine to Alanine Mutant Receptors1
 
 
 
hM1 Receptor 
Constructs pKD BBmax Hill Slope 
 WT () 
 9.57 ± 0.07 643.98 ± 69.9 1.48 ± 0.20 
2C-A (▲) 9.28 ± 0.05 885.06 ± 75.3 1.73 ± 0.07 
2CC (U) 8.95 ± 0.02* 1664.26 ± 102.3 * 1.82 ± 0.26 
4CC (V) 8.92 ± 0.10* 1983.78 ± 162.1 * 1.57 ± 0.15 
CC-AA () 9.04 ± 0.04** 1511.87 ± 17.1 ** 1.96 ± 0.26 
 
 
 
1Data presented in table represents data collected from saturation radioligand 
binding assay (Figure 11).  The KD (equilibrium dissociation constant), Bmax 
(maximal number of binding sites available) and Hill slope was estimated using 
nonlinear regression as described previously by Bowen and Jerman, 1995.  
Significantly different from WT (* denotes p < 0.001)(** denotes p < 0.01) was 
determined using a one way ANOVA and post hoc Bonferroni’s multiple selective 
comparison test. 
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3.7.3  Maximal Number of Binding Sites (Bmax) for Cysteine to Alanine 
 Mutant Receptors 
 
 In general, cysteine to alanine mutant receptors Bmax values were 
significantly (F5,19  = 18.45, p < 0.0001) increased compared to hM1/WT using a 
one way ANOVA.  Mutant receptors, hM1/2CC, 4CC, and CC-AA, exhibited 
greater receptor expression on the cell surface compared to hM1/WT (Table VII).  
In this experiment this increase in expression on the cell surface is consistent 
with the receptor internalization data because the mutant receptor extent of 
internalization was lower leaving more receptors on the cell surface.  For 
example, with hM1/2CC and 4CC the maximum receptor percent internalization 
was 18.3% (Table VI) leaving the majority of the receptors on the cell surface for 
the ligand to bind, correlating to the increase in maximal number of binding sites 
available.  hM1/CC-AA (Bmax = 1511.87 ± 17.1) had a deficient internalization 
response therefore the increase in maximal number of binding sites compared to 
hM1/WT (BBmax = 643.98 ± 69.9) would be expected as well as the maximal 
number of binding sites available be less than hM1/2CC, and 4CC.   
 Mutant receptor hM1/2C-A (Bmax 885.06 ± 75.3) has a maximal number of 
binding sites compared to hM1/WT (Bmax 643.98 ± 69.9).  Comparing the four 
mutant receptors made by changing cysteine(s) to alanine(s), hM1/2C-A 
internalized most similar to hM1/WT, therefore expected maximal binding sites 
available would be similar.   
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3.7.4  Agonist Potency of Cysteine to Alanine Mutant Receptors 
 
 To ascertain if the reduced agonist-dependent internalization of the 
cysteine to alanine receptor mutants was a consequence of loss of function of 
the receptor, CHO-K1 cells were transiently transfected with hM1/2CC, 4CC, CC-
AA, or 2C-A and phosphoinositide hydrolysis (PI) assay was performed as 
described in “Research Methods”.   
 In general, all cysteine to alanine mutant receptors were similar to hM1/WT 
in potency with no significant difference as determined using an one-way 
ANOVA.  The cysteine to alanine mutant receptor that had the most similar 
response to hM1/WT was hM1/2C-A with pEC50 of 5.34 ± 0.10 and 5.47 ± 0.05, 
respectively.   All cysteine to alanine mutant receptors caused an increase in the 
maximal response of the receptor induced by the agonist (Figure 12). 
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Table VIII.  Potency of Cysteine to Alanine Mutant Receptors  
 
hM1 Receptor Constructs pEC50
WT 5.34 ± 0.10 
4CC 5.67 ± 0.06  
2CC 5.60 ± 0.06 
2C-A 5.47 ± 0.05 
CC-AA 5.62 ± 0.03  
 
 
 
Data presented in table represents data collected from phosphoinositide 
hydrolysis assays (Figure 12).  The pEC50 was estimated using nonlinear 
regression as described previously by Bowen and Jerman, 1995.   
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Figure 12.  Cysteine to alanine mutant receptor comparison of phosphoinositide 
response to hM1/WT receptor.  hM1/2C-A (▲), hM1/2CC (U), hM1/4CC 
(V), and hM1/CC-AA() mutant receptors are shown in comparison to 
hM1/WT ().  CHO-K1 cells transiently expressing hM1 mutant receptors 
were incubated with [3H]myo-inositol (0.2 μM) 24 hours before performing 
phosphoinositide hydrolysis assay (see “Research Methods”).  Each data 
point represents an experiment conducted in triplicate either 3 or 4 times, 
± the S.E.M 
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Chapter IV 
 
 
 
Discussion 
 
 
 In a previous study, deletion of the 8 amino acid domain 254-TPPGRCCR-
262 from hM1 receptors was determined to decrease the extent of agonist-
dependent hM1 receptor internalization.  This decrease in internalization could 
not be attributed to a lack of ligand binding or loss of receptor signaling as 
determined in intact cell radioligand binding and phosphoinositide hydrolysis 
assays, respectively (unpublished results).  The primary objective of this study 
was to further these previous observations by trying to identify specific amino 
acid residues within or adjacent to this 8 amino acid domain that play a role in 
agonist-dependent hM1 receptor internalization.  To accomplish this objective, 
various amino acid residues were mutagenized within the domain 252-
PETPPGRCCRCC-263 of the hM1 receptor.  Each of the resulting hM1 receptor 
mutants was then characterized to determine the affect of the mutation on 
agonist-dependent internalization, ligand binding, and receptor signaling.  
 
4.1 Dimerization 
 The previous study, which identified the 8 amino acid domain in the i3 loop 
of hM1 receptors, focused on trying to determine whether or not domains of the
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 hM1 receptors were capable of interacting with one another to possibility mediate 
hM1 receptor dimerization.  Growing evidence supporting the postulate that 
muscarinic receptors dimerize under certain conditions was the incentive for the 
previous investigation.  To date, evidence for muscarinic receptor dimerization 
has been obtained in investigations using M2 and M3 receptor subtypes (Maggio 
et al., 1996; Park et al., 2001; Zeng and Wess, 2000; Zeng and Wess, 1999).   
 Using receptor chimeras composed of various segments of α2-adrenergic 
and M3-muscarinic receptors, it was established that GPCRs can interact with 
one another to form dimers (Maggio et al., 1996).  When a chimeric receptor 
(α2/M3) composed of transmembrane domains one through five of α2-adrenergic 
receptors fused with transmembrane domains six and seven of M3-muscarinic 
receptors was expressed in CHO cells, no [3H]NMS (muscarinic receptor-
selective radioligand) or [3H]rauwolscine (adrenergic receptor-selective 
radioligand) binding was observed (Maggio et al., 1996).  A similar result was 
obtained for a receptor chimera composed of transmembrane domains one 
through five of M3-muscarinic receptors fused with transmembrane domains six 
and seven α2-adrenergic receptors (M3/α2).  Interestingly, when these receptors 
were coexpressed (i.e., α2/M3 and M3/α2) in CHO cells, both [3H]NMS and 
[3H]rauwolscine binding was observed (Maggio et al., 1996).  These observations 
suggested that the α2/M3 and M3/α2 receptor chimeras were dimerizing and the i3 
loop of the M3 receptor was determined to mediate the interaction between the 
receptors (Maggio et al., 1996).  This also suggested that the i3 loop of M3 
receptors could mediate dimerization of M3 receptors alone, a postulate 
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investigated by Zeng and Wess (1999).  They determined that the i3 loop of M3 
receptors did not mediate M3 receptor dimerization, but cysteine residues in the 
extracellular loops of the M3 receptor did (Zeng and Wess, 1999).  One possible 
explanation for the contrast in results could be that lack of functional 
complementation seen by Maggio (1996) was due to steric hindrance, preventing 
exchange of the domains between the two chimeric receptors (Zeng and Wess, 
2000).  More recently, M2 receptors were found to dimerize when expressed in 
Sf9 cells, although the domain mediating the interaction has not been described 
to date (Park et al., 2001).   
 Along with the evidence for muscarinic receptor dimerization, other 
GPCRs have been observed to form dimers and dimerization of these receptors 
has been demonstrated to affect internalization.  Specifically, heterodimerization 
between opioid-δ and -κ receptors caused an increase in the rate of 
internalization when exposed to agonist (Jordan and Devi, 1999).  β2-adrengeric 
and opioid-receptor heterodimers have been observed to form and the 
consequence of this dimerization was to affect trafficking of both receptors.  
Therefore, the possibility that deleting 254-TPPGRCCR-262 from the i3 loop of 
hM1 receptors prevents hM1 receptor dimerization, resulting in decreased hM1 
receptor internalization, exists.  In future investigations, this possibility would be 
addressed by conducting co-immunoprecipitation studies using differentially 
tagged wild-type and mutant hM1 receptors to verify that wild type receptors 
dimerize and whether or not deletion of 254-TPPGRCCR-262 prevents 
dimerization.        
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4.2  Phosphorylation of hM1 Receptors 
 A protein sequence scan performed on the domain 254-TPPGRCCR-262 
and surrounding amino acid residues showed that a putative proline-dependent 
serine/threonine kinase phosphorylation site overlapped with the domain.  
Phosphorylation of GPCRs often leads to internalization.  Specifically, M1 
receptors have been shown to be phosphorylated at a specific serine- and 
threonine-rich site in the i3 loop by protein kinases in an agonist-dependent 
manner that is temporally consistent with removal of the receptor from the 
plasma membrane (Haga et al., 1996).  Once phosphorylated, arrestin may bind 
the phosphorylated domain, promoting the internalization of the receptor in 
clathrin-coated pits (Wu et al., 1997; Lefkowitz and Shenoy, 2005).  To date, the 
interaction between muscarinic receptors and arrestins have not been completely 
described and more research needs to be done to understand the mechanism by 
which arrestins mediate muscarinic receptor internalization.  
 To determine whether the putative proline-dependent serine/threonine 
kinase phosphorylation site identified plays a role in agonist-dependent hM1 
receptor internalization, a mutant hM1 receptor was made lacking the consensus 
sequence (i.e., hM1/T-A, see Figure 6) and then characterized.  As seen in Figure 
7 and Tables II and III, there was no difference in the carbachol-induced 
internalization of the hM1/T-A receptor mutant when compared to hM1-WT.  This 
observation suggests that the disruption of this putative phosphorylation site 
caused by deleting the domain 254-TPPGRCCR-262 from the i3 loop of hM1 
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receptors could not account for the decreased extent of carbachol-induced 
internalization of hM1/8aa del (see Figure 4).   
 
4.3  SH3 Binding Domain 
 Some GPCRs are known to contain SH3 domains, also known as SH3 
ligands, and can interact with proteins that possess SH3 binding domains which 
recognize the SH3 domain consensus sequence PXXP (Ren et al., 1993).  The 
protein motif scan conducted at the beginning of this investigation identified a 
putative SH3 domain overlapping with the domain 254-TPPGRCCR-262 (see 
Figure 6).  To determine whether the deletion of 254-TPPGRCCR-262 from 
hM1/8aa del disrupted this putative SH3 domain, resulting in the decreased 
extent of carbachol-induced hM1 receptor internalization, a proline to alanine 
point mutation was made to disrupt the putative site (Figure 6) and the resulting 
mutant (hM1/P-A) was characterized.  As seen in Figure 7 and Tables II and III, 
the hM1/P-A receptor mutant internalized in a manner similar to that observed for 
hM1-WT.   This observation suggests that the putative SH3 domain in the i3 loop 
of hM1 receptors does not play a role in carbachol-induced internalization.   
 
4.4  Cysteine to Alanine hM1 Receptor Mutants 
 Muscarinic receptor expression at the plasma membrane is based on an 
equilibrium that is established between pathways that bring the receptor to the 
cell surface and back into the intracellular realm.  Endocytosis refers to a diverse 
set of mechanisms that mediate receptor internalization, which often follows 
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receptor desensitization and can lead to receptor down-regulation.  Removal of 
the putative phosphorylation site and the SH3 binding domain did not affect hM1 
receptor internalization (see Figure 7).  This led us to speculate that the deletion 
of cysteine residues 259 and 260 in hM1/8aa del resulted in the decreased hM1 
receptor internalization seen previously (see Figures 4 and 6).  Therefore, the 
focus of this study moved to mutagenizing the cysteine residues within and 
surrounding the domain 254-TPPGRCCR-262 of hM1 receptors.   
 
4.4.1  Internalization of Cysteine to Alanine hM1 Receptor Mutants 
 Two mutant hM1 receptors were made possessing cysteines 262 and 263 
mutated to alanines (i.e., hM1/2CC and hM1/4CC; see Figure 6) and then 
characterized.  Both hM1/2CC and hM1/4CC receptor mutants were observed to 
have significantly different carbachol-induced internalization profiles when 
compared to hM1-WT (see Figure 10).  The hM1/4CC receptor mutant also had 
cysteine residues 259 and 260 mutagenized to alanines.  One other mutant, 
hM1/CC-AA (see Figure 6), had this pair of cysteines mutagenized.  The hM1/CC-
AA receptor mutant was also observed to have a significantly different carbachol-
induced internalization profile when compared to hM1-WT (see Figure 10).  
Overall, the data suggests that cysteine pairs 259-260 and 262-263 play 
important, but distinct roles in carbachol-induced hM1 receptor internalization.  
This postulate is supported by the experiments performed on all of the cysteine 
to alanine receptor mutants made and is further described below.      
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 The amount of receptor that internalized at the 0.5 hour time point was 
found to vary considerably between hM1-WT and the cysteine to alanine receptor 
mutants (see Figure 10 and Tables V and VI).  In general, the mutant receptors 
can be divided into two categories depending upon the extent of receptor 
internalization at the 0.5 hour time point.  The hM1/2C-A receptor mutant was 
observed to internalize in a manner consistent with hM1-WT receptors.  As seen 
in Figure 10, approximately 25% of total plasma membrane expressed hM1/2C-A 
receptor internalized after 0.5 hour incubation with carbachol (1 mM); consistent 
with approximately 22% of total plasma membrane expressed hM1-WT receptor.  
In contrast, very few hM1/CC-AA, hM1/2CC, and hM1/4CC receptors internalized 
after 0.5 hour incubation with carbachol (see Figure 10 and Tables V and VI).  
Approximately 3% of total hM1/CC-AA, hM1/2CC, and hM1/4CC mutant receptor 
expressed at the plasma membrane internalized at the 0.5-hour time point.  
Collectively, this data suggest that cysteine pair 259-CC-260 plays a role in this 
initial phase (i.e., 0 - 0.5 hour) of carbachol-induced hM1 receptor internalization.  
The exact role that cysteine pair 259-CC-260 plays in internalization is not known 
at this time, but we suspect that it may be forming disulfide linkages with the 
adjacent cysteine pair 262-CC-263 to stabilize an important 2o structure of the i3 
loop that is necessary for this initial phase of internalization to occur.   
This postulate is supported by the internalization of hM1/CC-AA, which 
lacks cysteine pair 259-CC-260 but has cysteine pair 262-CC-263 (see Figure 6).  
As seen in Figure 10, the hM1/CC-AA receptor mutant does not have an initial 
phase of internalization, which is similar to the hM1/2CC receptor mutant.   
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hM1/2CC has cysteine pair 259-CC-260, but does not have cysteine pair 262-CC-
263 (see Figure 6).  This suggests that the cysteine pairs are interacting with one 
another since the loss of either one result in the loss of the initial phase of 
carbachol-induced internalization.  The rescue of the initial phase of hM1 receptor 
internalization by the presence of cysteine 263 (i.e., hM1/2C-A receptor mutant; 
see Figure 6) further strengthens this claim.  As seen in Figure 10, the initial 
phase of carbachol-induced internalization is present for hM1/2C-A and is similar 
to that observed for hM1-WT.  So it would seem that the presence of a single 
cysteine in the pair 262-CC-263 is adequate for cysteine pair 259-CC-260 to form 
a bond.  This could be tested in a future study by creating an hM1 receptor 
mutant that has only cysteine 262.   
The extent of internalization of the hM1/2CC and hM1/4CC receptor 
mutants was also significantly different from the hM1-WT receptor during the later 
phase (i.e., 0.5 hour – 4 hour) of carbachol-induced internalization (see Figure 10 
and Tables V and VI).  These observations suggest that cysteine pair 262-CC-
263 is necessary for this phase of hM1 internalization.  Perhaps this pair of 
cysteine residues not only stabilizes a kink in the i3 loop of hM1 receptors by 
bonding cysteine pair 259-CC-260, but also is recognized by the internalization 
machinery of CHO cells.  Consequently, if the internalization machinery is 
prevented from binding the i3 loop of hM1 receptors by deleting cysteine pair 
262-CC-263, the receptor would not internalize when exposed to carbachol.  The 
internalization of the hM1/CC-AA receptor mutant supports this postulate (see 
Figure 10).  hM1/CC-AA lacks the cysteine pair 259-CC-260, but has cysteine 
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pair 262-CC-263 (see Figure 6).  As seen in Figure 10, it lacks the initial phase of 
internalization as described above, but has a later phase of internalization like 
hM1-WT.   
In further support of our observations, a disulfide bond between cysteine 
residues 140 and 220, connecting the first and second extracellular loops of 
adjacent M3 receptors has been described (Zeng and Wess, 2000).  This 
demonstrates that even nonadjacent cysteine residues can bond with one 
another.  Disulfide bonds between adjacent cysteine residues have also been 
described in a variety of proteins.  This type of bonding has been shown to cause 
a tight turn, or kink, in a polypeptide and the conformation of the kink has been 
shown to change depending upon the cellular environment (Carugo et. al., 2003).  
Perhaps this is the mechanism by which cysteine pairs 259-CC-260 and 262-CC-
263 play a role in carbachol-induced hM1 receptor internalization.  This possibility 
needs to be addressed in future studies.   
 
4.4.2  Affinity and Potency of Cysteine to Alanine hM1 Receptor Mutants 
 The binding of each mutant hM1 receptor was characterized and 
compared to that of hM1/WT receptor.  This was done to ensure that the affect of 
the various mutations on carbachol-induced internalization was not a 
consequence of the ligand being prevented from binding to the receptor.  As 
seen in Figure 11 and Table VII, all cysteine to alanine receptor mutants bound 
the muscarinic receptor-selective radioligand [3H]NMS.  This suggests that none 
of the mutations prevented ligand binding, thus resulting in altered receptor 
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internalization.  However, almost all of the cysteine to alanine point mutations 
made, caused a significant increase in the pKD values obtained from saturation 
binding assays when compared to hM1-WT (see Table VII).  While this increase 
was significant, it only amounted to an approximate 3-fold increase in pKD value.  
The pKD determined for carbachol binding hM1-WT receptors is approximately 6 
when the assay is conducted in the presence of guanine nucleotide (e.g., a 
condition similar to the carbachol-induced internalization assay performed on 
intact cells; unpublished observation).  Assuming that the affect of each cysteine 
to alanine mutation on [3H]NMS binding is similar to that for carbachol binding, 
near maximal receptor occupancy would be obtained for each receptor mutant, 
and would be comparable to that for hM1-WT receptors, at the concentration of 
carbachol used (1 mM).   
 In support of the above statement, the pEC50 values obtained for 
phosphoinositide hydrolysis elicited to carbachol for all cysteine to alanine hM1 
receptors (pEC50 = ~5.5) was comparable to that obtained for hM1-WT receptors 
pEC50 = 5.34 + 0.1; see Table VIII).  It should also be noted that the maximal 
response (Emax) obtained for each of the cysteine to alanine receptor mutants 
was equal to or greater than that obtained for hM1-WT receptors (see Figure 12).  
Collectively, these data suggest that all of the receptor mutants are signaling and 
that differences in the phosphoinositide response would not result in decreased 
hM1 receptor internalization.  In fact, one might expect the opposite since the 
magnitude of the phosphoinositide response elicited to carbachol was greater for 
hM1/2CC and hM1/4CC; both of which did not internalize.  Therefore, all of the 
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cysteine to alanine mutations affecting carbachol-induced internalization is not a 
consequence of preventing receptor signaling. 
 
4.5  Summary 
 Muscarinic acetylcholine receptors have been identified as GPCRs, a 
large family of seven transmembrane spanning receptors that couple to a variety 
of effectors to induce numerous intracellular signals.  Similar in structure, the 
muscarinic receptor subtypes (M1-M5) are composed of an extracellular amino-
terminus, an intracellular carboxyl-terminus, and alternating intracellular (1, 2, & 
3) and extracellular (1, 2, & 3) loops.  M1, M3, and M5 receptors couple to Gq/11 
proteins to metabolize phosphoinisitides whereas M2 and M4 receptors couple to 
Gi/o proteins to inhibit adenylate cyclase activity.  
 Previous observations made by our laboratory utilizing the yeast-two-
hybrid system showed that an 8 amino acid domain (254-TPPGRCCR-261) in 
the human muscarinic receptor (hM1) i3 loop mediates an interaction with itself.  
Various pharmacological assays were preformed to determine the functional role 
of this domain.  It was concluded that a mutant hM1 receptor lacking the domain 
254-TPPGRCCR-261 internalized differently than wild-type hM1 receptors when 
exposed to the muscarinic receptor-selective agonist carbachol, whereas affinity 
of [3H]NMS binding and the potency of phosphoinositide hydrolysis elicited to 
carbachol were similar. 
 The emphasis of this research was to further characterize this small 
domain in the third intracellular loop of the hM1 receptor.  Using site-directed 
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mutagenesis, several mutant hM1 receptors were made possessing different 
point mutations within the domain 252-PETPPGRCCRCCR-264.  Wild-type and 
mutant hM1 receptors were transiently expressed in CHO cells and the effect of 
each point mutation(s) on ligand affinity, agonist potency, and agonist-induced 
internalization was determined.  The equilibrium dissociation constant (KD)  
determined from intact cell [3H]NMS binding assays was similar for all mutant 
hM1 receptors (pKD = ~ 9.1) tested and was comparable to that obtained for wild 
type receptors (pKD = 9.57 ± 0.07).  Similarly, the concentration of carbachol 
eliciting half-maximal phosphoinositide hydrolysis (EC50) was comparable 
between mutant (pEC50 = ~5.5) and wild type (pEC50 = 5.34 ± 0.10) hM1 
receptors.   Overall, these binding and potency data indicate that none of the 
point mutations made prevented ligand binding or signaling of hM1 receptors, 
respectively.   In contrast to the binding and functional data, carbachol-induced 
internalization of mutant hM1 receptors possessing either 259-CysCys/AlaAla, 
262-CysCys/AlaAla, or 263 Cys/Ala point mutations was significantly reduced 
when compared to that of wild type receptors.  These observations strongly 
suggest that cysteine pairs 259-260 and 262-263 play a role in the agonist-
dependent internalization of hM1 receptors, perhaps by mediating receptor 
dimerization/oligomerization.  
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